Nephrology

Chiadi Ndumele, MD, PhD, MHS, of Johns Hopkins University, details features of the new 4-stage construct that guides CKM diagnosis and promotes early disease intervention.

Ndumele chairs the American Heart Association committee that characterized the syndrome and wrote the statement of evidence for its assessment and management.

The phase 3 semaglutide kidney outcomes trial will be stopped immediately with FLOW read out expected in early 2024, the company said.

The prevalence of cardiac, renal, and metabolic conditions has significantly increased over 20 years and so has the number of US adults who have all 3.

Empagliflozin is approved to lower the risk of sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with CKD at risk of progression.

The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.

A daily dose of clinical news on Patient Care you may have missed.

A daily dose of clinical news on Patient Care you may have missed.

Among persons with hypertension and T2D with albuminuria, nearly two-thirds currently go undetected, a significant barrier to diagnosis and treatment of CKD.

Investigators identified 6 blood pressure patterns that, when combined with other risk factors, accurately stratified risk of hypertensive disorders of pregnancy.

KidneyIntelX.dkd, a first-in-class AI-enabled prognostic test, stratifies risk of DKD progression in 5 years and is specific for early stage disease.

Your daily dose of clinical news you may have missed.

SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.

A recent American Kidney Fund survey of 300 primary care and specialty clinicians found ~15% of their patients had kidney disease of unknown origin.

This topline look at the KDIGO 2022 updated guideline highlights new recommendations for clinical use of SGLT2i, GLP-1 RA, and nonsteroidal MRA.

Find a compact sampling of 2022 chronic kidney disease research reviewed on Patient Care, chosen by the editorial staff.

Peer mentor programs can provide support for patients, especially when it comes to family planning and parenthood.

Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.

The findings underscore the importance of routine eGFR and UACR screening in primary care to ensure early detection of CKD and avoid related adverse outcomes.

CMHC. PCPs and cardiologists appeared to perform only half of items considered necessary for care of T2D patients in a new simulated patient study.

Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.

Dr Maruthur, a primary care physician, helped develop the new ADA/EASD consensus report on T2D management and has suggestions.

Dr Maruthur, of Johns Hopkins Medicine, talks about how the concept of "holistic" patient care continues to expand in the management of persons with T2D.

The new consensus recommends holistic, person centered care focused on glycemic and weight management, CV risk reduction, and cardiorenal organ protection.